Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Biotech Hedge Fund Titan, Isaly, Steps Down Amid Sexual Harassment Claims December 7, 2017 Bioverativ Appoints Executive Vice President, Research And Development April 9, 2017 Clinigen And Cumberland Pharmaceuticals Launch Totect In The U.S. For Emergency Oncology Intervention September 24, 2017
Clinigen And Cumberland Pharmaceuticals Launch Totect In The U.S. For Emergency Oncology Intervention September 24, 2017